Next generation T cell therapies for solid cancers.

Abstract

Tumor-infiltrating lymphocytes show consistent clinical benefit in metastatic melanoma, but they are a poorly defined product with variable antitumor activity. In this issue, Palmer et al.¹ create for clinical testing a cell product consisting of highly functional tumor-reactive T cells by knocking out CISH, an inhibitor of T cell activation.